Memorial Sloan-Kettering Cancer Center

Summary

Organization: Memorial Sloan-Kettering Cancer Center
Country: USA

Top Publications

  1. pmc Controversies in the treatment of Burkitt lymphoma in AIDS
    Ariela Noy
    Hematology Division, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Opin Oncol 22:443-8. 2010
  2. ncbi A fetal cyclooxygenase-2 gene polymorphism is associated with placental malperfusion
    Alexandros D Polydorides
    Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, New York, New York, USA
    Int J Gynecol Pathol 26:284-90. 2007
  3. ncbi Exploration of the construct of reliance among patients who talk with their providers about internet information
    Carma L Bylund
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    J Health Commun 12:17-28. 2007
  4. ncbi Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma
    Lawrence T Dauer
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Health Phys 92:33-9. 2007
  5. ncbi Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 67:327-33. 2007
  6. ncbi Chronic health conditions in adult survivors of childhood cancer
    Kevin C Oeffinger
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 355:1572-82. 2006
  7. ncbi The community barometer: a breast health needs assessment tool for community-based organizations
    David Lounsbury
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Health Educ Behav 33:558-73. 2006
  8. ncbi 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI
    Heiko Schoder
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 47:755-62. 2006
  9. ncbi Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging
    Oguz Akin
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 239:784-92. 2006
  10. ncbi Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1395-403. 2006

Detail Information

Publications62

  1. pmc Controversies in the treatment of Burkitt lymphoma in AIDS
    Ariela Noy
    Hematology Division, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Opin Oncol 22:443-8. 2010
    ..Increasingly then, the risks of HIV associated cancers become paramount. Burkitt lymphoma is one of the cancer subtypes highly disproportionately affecting HIV infected patients...
  2. ncbi A fetal cyclooxygenase-2 gene polymorphism is associated with placental malperfusion
    Alexandros D Polydorides
    Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, New York, New York, USA
    Int J Gynecol Pathol 26:284-90. 2007
    ..Thus, a fetal polymorphism in the COX-2 gene influences the occurrence of placental malperfusion and ischemia, which may be of sufficient severity to promote or allow the development of IUGR...
  3. ncbi Exploration of the construct of reliance among patients who talk with their providers about internet information
    Carma L Bylund
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    J Health Commun 12:17-28. 2007
    ..Age, comfort level, and frequency of talking about Internet health information were not related to reliance level...
  4. ncbi Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma
    Lawrence T Dauer
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Health Phys 92:33-9. 2007
    ....
  5. ncbi Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 67:327-33. 2007
    ..To assess long-term prostate-specific antigen (PSA) outcome after permanent prostate brachytherapy (BT) and identify predictors of improved disease-free survival...
  6. ncbi Chronic health conditions in adult survivors of childhood cancer
    Kevin C Oeffinger
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 355:1572-82. 2006
    ..Only a few small studies have assessed the long-term morbidity that follows the treatment of childhood cancer. We determined the incidence and severity of chronic health conditions in adult survivors...
  7. ncbi The community barometer: a breast health needs assessment tool for community-based organizations
    David Lounsbury
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Health Educ Behav 33:558-73. 2006
    ..Four case studies are presented. Limitations of the instrument and its administration in community settings as well as future research objectives are discussed...
  8. ncbi 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI
    Heiko Schoder
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 47:755-62. 2006
    ..In particular, the value of combined PET/CT has not been determined in this group of patients...
  9. ncbi Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging
    Oguz Akin
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 239:784-92. 2006
    ....
  10. ncbi Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1395-403. 2006
    ..Hepatic metastases derive most of their blood supply from the hepatic artery; therefore, for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome...
  11. ncbi Targeting histones and proteasomes: new strategies for the treatment of lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Box 329, 1275 York Ave, New York, NY 1002, USA
    J Clin Oncol 23:6429-36. 2005
    ..In this article, we will review some of the prevailing theories about how these novel targeted drugs affect lymphoma biology, and how these compounds are changing the face of lymphoma therapy...
  12. ncbi Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells
    Jakob Dupont
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Joan and Sanford Weill Medical College of Cornell University and Immunology Program, Sloan Kettering Institute, New York, New York 10021, USA
    Cancer Res 65:5417-27. 2005
    ....
  13. ncbi Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme
    Lauren E Abrey
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Neurol Neurosci Rep 5:167-8. 2005
  14. ncbi Long-term enteral nutrition facilitates optimization of body weight
    Mark A Schattner
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    JPEN J Parenter Enteral Nutr 29:198-203. 2005
    ..Optimization of body mass index (BMI) among cancer survivors is a priority. Long-term enteral nutrition is required by many head and neck cancer survivors and may be utilized to affect changes in BMI...
  15. ncbi Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays
    Alex J Rai
    Memorial Sloan Kettering Cancer Center, Department of Clinical Laboratories, 1275 York Avenue, Box 88, New York, NY 10021, USA
    Expert Rev Mol Diagn 7:545-53. 2007
    ..Finally, regulatory considerations that need to be addressed before a biomarker assay is commercialized are discussed briefly...
  16. ncbi Death anxiety and cancer-related stigma: a terror management analysis
    Catherine E Mosher
    University of Albany, State University of New York, Albany, New York, USA and Memorial Sloan Kettering Cancer Center, Department of Psychiatry and Behavioral Sciences, 641 Lexington Avenue, 7th Floor, New York, NY 10022, USA
    Death Stud 31:885-907. 2007
    ..Findings partially support terror management theory and suggest that death attitudes, gender norms, and diagnostic status influence social distancing from individuals with cancer...
  17. ncbi The multidisciplinary management of gastrointestinal cancer. Colorectal cancer screening
    Sidney J Winawer
    Gastroenterology and Nutrition Service, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, Box 90, New York, NY 10021, USA
    Best Pract Res Clin Gastroenterol 21:1031-48. 2007
    ..However, screening rates are low and many barriers are present that need to be overcome in order to make a major global impact on colorectal cancer incidence and mortality...
  18. doi Advances in the treatment of malignant gliomas
    Mustafa Khasraw
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Oncol Rep 12:26-33. 2010
    ..This review focuses on recent advances in the treatment malignant gliomas, especially antiangiogenic therapy...
  19. doi Optimization of collimator trajectory in volumetric modulated arc therapy: development and evaluation for paraspinal SBRT
    Pengpeng Zhang
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 77:591-9. 2010
    ..To develop a collimator trajectory optimization paradigm for volumetric modulated arc therapy (VMAT) and evaluate this technique in paraspinal stereotactic body radiation therapy (SBRT)...
  20. pmc Distinct responses of human monocyte subsets to Aspergillus fumigatus conidia
    Natalya V Serbina
    Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 183:2678-87. 2009
    ..Our study demonstrates that functional CD14(+)CD16(-) and CD14(+)CD16(+) monocytes can be isolated from allogeneic hematopoietic stem cell transplantation donors and that these subsets differ in their response to A. fumigatus conidia...
  21. pmc Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction
    Martin Jechlinger
    Program in Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Genes Dev 23:1677-88. 2009
    ..Moreover, cells in the surviving spheres retain the ability to respond to reinduction and thus may represent the type of cells that give rise to recurrent tumors...
  22. pmc Molecular orchestration of differentiation and function of regulatory T cells
    Li Fan Lu
    Howard Hughes Medical Institute and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Genes Dev 23:1270-82. 2009
    ..In this review, we discuss the molecular aspects of Treg cell lineage commitment, maintenance, and function...
  23. doi Large congenital melanotic nevi in an extremity with neurocutaneous melanocytosis
    Oren J Becher
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA
    Pediatr Dermatol 26:79-82. 2009
    ..In our case, cerebrospinal fluid studies were not reliable even in the face of florid neurocutaneous melanocytosis involving the leptomeninges and ventricles...
  24. pmc Membrane bound axin is sufficient for Wingless signaling in Drosophila embryos
    Nicholas S Tolwinski
    Program in Developmental Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Genetics 181:1169-73. 2009
    ..I find that nuclear localization of APC2 appears to be required, but Axin can block signaling when tethered to the membrane. These results support the model where Axin regulates Armadillo localization and activity in the cytoplasm...
  25. doi Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays
    Sacha Gnjatic
    Ludwig Institute for Cancer Research at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol Methods 341:50-8. 2009
    ....
  26. doi A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors
    Archie N Tse
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:6704-11. 2008
    ..We conducted a phase I study of irinotecan and the Hsp90 inhibitor 17AAG, which can also down-regulate Chk1, in patients with solid tumors...
  27. pmc Structural insights into amino acid binding and gene control by a lysine riboswitch
    Alexander Serganov
    Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 455:1263-7. 2008
    ....
  28. ncbi Dosimetric and anatomic indicators of late rectal toxicity after high-dose intensity modulated radiation therapy for prostate cancer
    Reshma Munbodh
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Med Phys 35:2137-50. 2008
    ..Late rectal toxicity was related to the irradiation of the upper part of the rectum and also to the absolute area irradiated, PTV size, and rectum size on the planning computed tomography (CT) scan...
  29. doi Treatment outcomes for patients with synovial sarcoma of the head and neck
    Nancy Lee
    Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, NY, USA
    Expert Rev Anticancer Ther 8:371-3. 2008
    ..This paper highlights the importance of a multidisciplinary approach in the treatment of this disease...
  30. doi Individualized prediction of colon cancer recurrence using a nomogram
    Martin R Weiser
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:380-5. 2008
    ..Although easy to implement, there remains significant heterogeneity within each stage grouping. In the era of multimodality treatment, a more refined tool is needed to predict recurrence...
  31. ncbi Laparoscopy and malignancy
    Chandrakanth Are
    Department of Surgery, The Johns Hopkins Medical Institution, Baltimore, Maryland, USA
    J Laparoendosc Adv Surg Tech A 15:38-47. 2005
    ..The aim of this section is to review the current literature and attempt to obtain a consensus of the role of laparoscopy in the treatment of cancer...
  32. ncbi Gemcitabine and docetaxel in metastatic breast cancer
    Andrew D Seidman
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 18:13-6. 2004
    ..Results of this trial will help to determine optimal use of taxane-based combinations in patients with advanced disease...
  33. ncbi Breast imaging and the conservative treatment of breast cancer
    D David Dershaw
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Radiol Clin North Am 40:501-16. 2002
    ..Mammography and other imaging modalities, such as sonography and MRI, assist in the determination of the appropriateness of breast conservation and in the differentiation of recurrence from benign sequelae of treatment...
  34. ncbi The involved field is back: issues in delineating the radiation field in Hodgkin's disease
    J Yahalom
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Ann Oncol 13:79-83. 2002
    ..In this manuscript we review the comeback of the involved field, address design questions and offer field borders for common disease sites...
  35. ncbi Potential of the proteasomal inhibitor MG-132 as an anticancer agent, alone and in combination
    D Banerjee
    Sloan Kettering Institute for Cancer Research, Molecular Pharmacology and Experimental Therapeutics Program, New York, NY 10021, USA
    Anticancer Res 21:3941-7. 2001
    ..Further, MG-132 inhibits CFU-GM colony formation of the CD34+ enriched PBSC population and this inhibition correlates with release of cyt C into the cytosol...
  36. ncbi Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors
    Guenther Koehne
    Department of Pediatrics, Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 99:1730-40. 2002
    ..Strikingly, the CD4(+)IFN-gamma(+) cell fractions were not cytotoxic against EBV-transformed or allogeneic targets...
  37. ncbi The evolving role of gemcitabine in the management of breast cancer
    A D Seidman
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncology 60:189-98. 2001
    ..The search for active agents to this end has recently included the clinical evaluation of the novel nucleoside analogue gemcitabine (2',2'-difluorodeoxycytidine). This review summarizes the recent and current development of this agent...
  38. ncbi Applications of molecular diagnostics: solid tumor genetics can determine clinical treatment protocols
    C Cordon-Cardo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mod Pathol 14:254-7. 2001
    ..The molecular characterization therefore has an important prognostic and practical role in diagnosis...
  39. ncbi Recent advances in hepatic resection
    R P DeMatteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Surg Oncol 19:200-7. 2000
    ..We present a summary of our experience with these advances...
  40. pmc Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele
    S Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 97:10917-22. 2000
    ..The approach described here allows monitoring of CD8(+) T cell responses to NY-ESO-1 in the context of various HLA alleles and has led to the definition of NY-ESO-1 peptides presented by HLA-Cw3 and HLA-Cw6 molecules...
  41. ncbi Cadherin-mediated adhesion at the interneuronal synapse
    J L Bruses
    Cellular Biochemistry and Biophysics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Cell Biol 12:593-7. 2000
    ....
  42. ncbi Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer
    S L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 46:859-64. 2000
    ..Nasopharynx cancer is a rare malignancy in childhood. This study aims to determine the role of chemotherapy, the optimal dose of radiation, and the long-term outcome for children with locoregional disease...
  43. ncbi Efficacy of conventional monitoring techniques in free tissue transfer: an 11-year experience in 750 consecutive cases
    J J Disa
    Plastic and Reconstructive Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Plast Reconstr Surg 104:97-101. 1999
    ..To enhance earlier identification of flap compromise in buried free flaps, alternative monitoring techniques such as implantable Doppler probes or exteriorization of flap segments are recommended...
  44. ncbi Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mod Pathol 12:786-93. 1999
    ..001). The frequencies of expression of ER and PR in SGCs and BCs metastatic to skin were not significantly different...
  45. ncbi Cytokine production by CD4+ T-cells responding to antigen presentation by melanoma cells
    M S Brady
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Melanoma Res 9:173-80. 1999
    ..Our data suggest that differential cytokine production by CD4+ T-cells in response to peptide presentation by HLA class II expressing tumour cells may contribute to tolerance to tumour antigens...
  46. pmc Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposure
    Bhuvanesh Singh
    Laboratory of Epithelial Cancer Biology, Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, USA
    BMC Genet 3:22. 2002
    ..We used comparative genomic hybridization (CGH) to screen for the genetic aberrations in 71 patients with head and neck squamous cell carcinoma and stratified the findings by the status of tobacco/alcohol exposure...
  47. ncbi Formulary management strategies for type 3 serotonin receptor antagonists
    Charles D Lucarelli
    Pharmaceutical Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Am J Health Syst Pharm 60:S4-11. 2003
    ..The use of special order forms improved compliance with the practice guidelines...
  48. ncbi Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 21:99-101. 2003
    ..The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC...
  49. ncbi Nausea & vomiting in end-stage cancer
    Anne Haughney
    Memorial Sloan Kettering Cancer Center, New York City, USA
    Am J Nurs 104:40-8; quiz 49. 2004
  50. ncbi Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:676-84. 2005
    ..To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL)...
  51. ncbi Postmastectomy CT-based electron beam radiotherapy: dosimetry, efficacy, and toxicity in 118 patients
    Marnee M Spierer
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 60:1182-9. 2004
    ..To evaluate the technique, dosimetry, acute and late toxicity, local control (LC), and overall survival (OS) with the use of computed tomography (CT)-based postmastectomy electron beam therapy (PMEBT) in high-risk patients...
  52. ncbi Circular binary segmentation for the analysis of array-based DNA copy number data
    Adam B Olshen
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Biostatistics 5:557-72. 2004
    ..The method is evaluated by simulation and is demonstrated on cell line data with known copy number alterations and on a breast cancer cell line data set...
  53. ncbi High-dose chemotherapy in breast cancer
    Diana E Lake
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Drugs 64:1851-60. 2004
    ..However, ongoing study of drug administration intervals, that is, dose-dense therapies, may lead to an approach that allows superior and less toxic treatment for breast cancer...
  54. ncbi Psychotherapeutic interventions at the end of life: a focus on meaning and spirituality
    William Breitbart
    Psychiatry Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Can J Psychiatry 49:366-72. 2004
    ..We further explore spiritual and existential themes through this meaning-oriented approach that encourages dying patients to find meaning and purpose in living until their death...
  55. ncbi Staging and response to therapy of malignant pleural mesothelioma
    Robert Heelan
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Lung Cancer 45:S59-61. 2004
    ..Patients response to therapy can be measured using the response evaluation criteria in solid tumors (RECIST) criteria involving multiple measurements of a single diameter of tumour thickness...
  56. ncbi Recent advances in bladder cancer diagnostics
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Biochem 37:562-71. 2004
    ..This review summarizes the reports utilizing high-throughput microarrays in bladder cancer and the implications of these analyses in the diagnosis and clinical management of patients with bladder cancer...
  57. ncbi Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 45:559-66. 2004
    ..Previous studies suggested that measurements of (18)F-FDG accumulation in tissue might be affected by the image reconstruction method, but the clinical relevance of these findings has not been assessed...
  58. ncbi Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer
    Padmanee Sharma
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 3:19. 2003
    ..This patient's T-cell response was determined to be specific for a new NY-ESO-1 epitope, p94-102, in the context of HLA-B35...
  59. ncbi Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology Program, Sloan Kettering Institute, New York, New York, 10021, USA
    Clin Cancer Res 9:3329-37. 2003
    ..The impact of KIT mutation in other regions, such as the extracellular or kinase domains, is not well-defined and fewer than 30 cases have been published to date...
  60. ncbi Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma
    Suzanne L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10021, USA
    J Clin Oncol 21:3079-83. 2003
    ..To assess the patterns of failure for patients with medulloblastoma receiving a conformal tumor bed boost rather than a boost to the entire posterior fossa...
  61. ncbi Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 25:601-5. 2003
    ..Although toxicity was generally thought to be mild, the efficacy of such an approach remains unproven...
  62. ncbi Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 15:2807-17. 1997
    ..To measure the sensitivity of histologic examination in detecting metastatic solid tumor in bone marrow...

Research Grants62

  1. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
    ....
  2. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert J Motzer; Fiscal Year: 2011
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  3. CLINICAL TRIALS AND MENTORING IN ONCOLOGY RESEARCH
    Robert Motzer; Fiscal Year: 2003
    ..One recently joined staff at MSKCC in the Genito-urinary Section. Mentoring of clinical trials is extended beyond fellowship to junior faculty members. ..
  4. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert Motzer; Fiscal Year: 2007
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  5. Meaning-Centered Group Psychotherapy in Advanced Cancer
    William Breitbart; Fiscal Year: 2007
    ....
  6. Meaning-Centered Psychotherapy in Advanced Cancer
    William Breitbart; Fiscal Year: 2002
    ..Larger, randomized controlled trials of Meaning-Centered Group Psychotherapy will be conducted in the future utilizing the insights learned from this pilot intervention study. ..
  7. Depression, Cytokines, and Pancreatic Cancer
    William Breitbart; Fiscal Year: 2006
    ..abstract_text> ..
  8. DEPRESSION/DESIRE FOR DEATH IN TERMINAL CANCER PATIENTS
    William Breitbart; Fiscal Year: 2003
    ..This study is expected to provide a direct evaluation of desire for death in terminally ill cancer patients, and to ascertain whether a pharmacological treatment for depression influences desire for death. ..
  9. DESIRE FOR DEATH AMONG TERMINALLY ILL PATIENTS WITH AIDS
    William Breitbart; Fiscal Year: 2001
    ....
  10. Individual Meaning-Centered Psychotherapy in Advanced Cancer Patients
    William Breitbart; Fiscal Year: 2010
    ....
  11. Meaning-Centered Group Psychotherapy in Advanced Cancer
    William Breitbart; Fiscal Year: 2010
    ..novel and innovative psychotherapy intervention for patients with advanced cancer, incorporating spiritual (meaning-centered) elements, which holds great promise in the treatment of spiritual suffering at the end-of-life ..
  12. Hepatic Arterial Flouridine and IV Bevacizumab for Primary Hepatic Malignancy
    William Jarnagin; Fiscal Year: 2007
    ..Furthermore, several important clinical issues are addressed by the proposed correlative studies, the results of which would be of broad general interest in clinical oncology. ..
  13. Beta glucan enhances antibody therapy for neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2003
    ..These findings will have general implications for antibody and vaccine strategies in human cancer models, and the role of polysaccharides as complementary/herbal medicine in immune-based therapies. ..
  14. A novel set of molecular markers to measure metastatic neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2007
    ..Armed with the tools to collect samples expeditiously and to measure MRD accurately, the paradigm of treating subclinical NB can then be tested in multicenter randomized studies. ..
  15. Radioimmunotherapy for Prostate Cancer
    Michael Morris; Fiscal Year: 2007
    ..The acquisition of these skills combined with the completion of the research plan will allow the candidate to pursue such research independently. ..
  16. GLOBIN GENE TRANSFER FOR THERAPY OF SICKLE CELL ANEMIA
    Michel Sadelain; Fiscal Year: 2004
    ....
  17. CANCER AND LEUKEMIA GROUP B
    Clifford Hudis; Fiscal Year: 2007
    ..The enclosed grant will provide resources for continued participation in the CALGB and for increased contributions by MSKCC to the group's success. ..
  18. The Secondary Prevention of Melanoma
    Susan Oliveria; Fiscal Year: 2007
    ..abstract_text> ..
  19. Development of HTS assays probing Hsp90 inhibition (RMI)
    Gabriela Chiosis; Fiscal Year: 2004
    ..Hits resulted from the FP assay will be tested for Her2 degradation potency in the breast cancer cell line SKBr3. Highest ranking compounds in both screens will be taken for further testing in follow-up research programs. ..
  20. A NEW FUNCTIONAL EVALUATION TOOL FOR CANCER CARE
    Peter Bach; Fiscal Year: 2004
    ..4) Instrument assembly through analysis of results of reliability and validity testing, followed by dissemination of results. ..
  21. Hsp90 inhibitors as suppressors of protein misfolding toxicity
    Gabriela Chiosis; Fiscal Year: 2007
    ..In conclusion, Hsp90- interfering drugs represent a potential novel class of drugs to promote the survival of neurons and open up a promising approach to the treatment of neurodegenerative diseases. ..
  22. THERAPY OF HEPATIC METASTASES FROM COLORECTAL CARCINOMA
    Nancy Kemeny; Fiscal Year: 1993
    ..FUR has a high hepatic extraction; we will test teroxirone extraction. both drugs are effective against colon cancer cell lines (Bertino - I-R01)...
  23. Validation of Medicare Claims to Define Chemotherapy Use
    Deborah Schrag; Fiscal Year: 2005
    ..This knowledge has the potential to lay the groundwork for development of an inexpensive and efficient system for monitoring and improving the quality of US cancer care. ..
  24. Isolation of Inhibitors of Her-Kinase Expression (RMI)
    Gabriela Chiosis; Fiscal Year: 2005
    ..To our knowledge, this has not been accomplished, and we believe that we are uniquely positioned to initiate this goal. ..
  25. The impact of androgen ablation therapy on cognition in*
    Christian Nelson; Fiscal Year: 2006
    ..2. To determine the severity of cognitive impairment in men over the age of 65 who have received androgen ablation therapy for 2 years. ..
  26. UNDERSTANDING RACIAL DIFFERENCES--LUNG CANCER TREATMENT
    Peter Bach; Fiscal Year: 2003
    ..Once identified, differences in the evaluative process undergone by black and white patients will be assessed, and the association between provider and patient race on receipt of surgery will be tested. ..
  27. GENETIC PREDISPOSITION TESTING IN COLORECTAL CANCER
    Deborah Schrag; Fiscal Year: 2002
    ..abstract_text> ..
  28. Roots of Health Disparities: The Quality of Primary Care
    Peter Bach; Fiscal Year: 2007
    ..The significance of these findings would be that a singular approach to improving the quality of care provided by physicians should enhance care quality overall and reduce healthcare disparities. ..